NMRA Stock Forecast & Price Target

Neumora Therapeutics is positioned for meaningful value creation because its clinical-stage CNS pipeline is built around a precision-medicine strategy for underserved disorders such as MDD, BPD, and AD agitation, giving it multiple shots on goal across both neuropsychiatric and neurodegenerative disease categories. The company’s most advanced asset, navacaprant, has KOASTAL-2 and KOASTAL-3 data expected in 1Q26 and 2Q26, while additional catalysts include NMRA-511 MAD data in 4Q26, NMRA-898 Phase 1 data in 2H26, and a 2026 clinic entry for NMRA-215, supporting a visible multi-year development path. Financially, the planned 35% workforce reduction should lower annualized costs by about $10 million despite roughly $2 million of one-time restructuring costs, and the current cash balance is expected to fund operations into 3Q27, providing runway through several key readouts.

Neumora Therapeutics is facing a fundamentally weaker investment case after navacaprant’s Phase 3 KOASTAL-2 and KOASTAL-3 studies failed to meet primary or key secondary endpoints, prompting discontinuation of the asset and stripping away a major source of anticipated value from the pipeline. The setback is especially damaging because the company had previously pointed to navacaprant as a differentiated MDD program with US sales potential of $750M in 2028 and $3B at peak, so its removal materially reduces both the commercial opportunity and the credibility of the broader development strategy. With the story now relying on earlier-stage programs such as NMRA-898, NMRA-511, and NMRA-215, each still carrying clinical uncertainty despite upcoming catalysts over the next 12–18 months, the outlook remains negative due to concentrated pipeline risk and limited near-term proof of durable value creation.